Aspire Biopharma Reports Q3 2025 Update and Advances Sublingual Drug Delivery Programs
I'm PortAI, I can summarize articles.
Aspire Biopharma Holdings Inc. provided a Q3 2025 business update, highlighting advancements in sublingual drug delivery. The company expanded its team with Dr. Mark J. Jaroszeski and reported progress on its sublingual ED medication program, aiming for a Phase 1 study by mid-2026. Aspire plans an NDA submission for sublingual aspirin in early 2026 and noted commercial success with Buzz Bomb Caffeine. An omnibus patent application was filed to enhance protection for its drug delivery system.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments